- Dudley was previously chief scientific officer of Tempus Labs
- He was also founding director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai
- Innovation Endeavors invests in cybersecurity, agriculture, logistics, construction, transportation, digital media and enterprise software
Early-stage venture firm Innovation Endeavors has named Joel Dudley as a partner.
Dudley joins Innovation Endeavors from Tempus Labs Inc, where he served as chief scientific officer. Before joining Tempus, Dudley was the associate professor of genetics and genomic sciences and founding director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. He also served as executive vice president for Precision Health for the Mount Sinai Health System.
Dudley has a BS in Microbiology from Arizona State University and an MS and doctorate in Biomedical Informatics from Stanford University School of Medicine.
“As a scientist and technologist, Joel brings a unique perspective to companies built at the intersection of life sciences and computer science,” Innovation Endeavors founding partner Dror Berman said in a statement. “Additionally, his experience as an entrepreneur allows him to partner with scientists in building generational companies.”
Founded in 2010, Innovation Endeavors is based in Palo Alto, California. “The firm’s central investment thesis, the Super Evolution, combines data, leading-edge computation, and advanced engineering to transform a range of industries, including agriculture, supply chain, the life sciences, transportation and more,” it said in the statement.
The firm’s biotech investments include Bolt Threads, Character Bioscience, Dewpoint Therapeutics, Eikon Therapeutics, Freenome, GRO Biosciences, Ukko, Viz.ai, Vicarious Surgical and Zymergen.